Role of PTK-7 in Acute Myeloid Leukemias

Institut Paoli-Calmettes10 enrolled

Overview

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans. It is also expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. In AML, PTK7 seems to convey promigratory and antiapoptotic signals into the cell and represents an independent prognosis factor of survival in patients treated with induction chemotherapy. This study aims at: * evaluating the impact of PTK7 expression on primary AML cells ex vivo * evaluating the diagnostic and prognostic value of a soluble form of PTK7

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Acute Myeloid Leukemia

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age\> 18 years * AML at diagnosis, not previously treated * Treatment by induction chemotherapy * Signed informed consent * Affiliation to the French social security system Exclusion Criteria: * pregnant woman(or of childbearing potential) or breastfeeding woman * emergency * patients deprived of liberty or placed under the authority of a tutor

Outcomes

Primary Outcomes

Evaluation PTK7+ and PTK7- AML cells hematopoietic homing abilities in xenografted mice by in vivo bioluminescence imaging

Time frame: 1 day

Soluble PTK7 measurement in the serum

Time frame: 12 years